Factors associated with COVID-19 susceptibility and severity in patients with multiple sclerosis: A systematic review

Published on Jun 15, 2021in medRxiv1.057
路 DOI :10.1101/2021.06.11.21258765
Mahdi Barzegar8
Estimated H-index: 8
(IUMS: Isfahan University of Medical Sciences),
bagherieh S1
Estimated H-index: 1
(IUMS: Isfahan University of Medical Sciences)
+ 6 AuthorsAram Zabeti4
Estimated H-index: 4
(UC: University of Cincinnati)
Background: We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS). Methods: Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-19 or its outcome in patients with MS on univariate or multivariate regression analyses. Results: Out of the initial 2719 records and 1553 conference abstracts, a total of 20 studies were included. Factors associated with COVID-19 susceptibility were reported in 11 studies and risk factors for infection outcomes were discussed in 10. History of contact with an infected is strongly suggested as a risk factor for COVID-19 susceptibility. Other factors that could be associated with contracting infection are younger age, relapsing course, and anti-CD20 agents. The evidence suggests that increasing age, greater MS severity, treatment with anti-CD20 agents, previous use of corticosteroids, and specific comorbidities (obesity and coronary artery disease) could be independently associated with worse infection outcomes. Male sex is likely to be a risk factor for more severe disease. The black or African American race was reported as a possible risk factor. null Conclusion: Due to a paucity of research and methodological issues, no risk factors for COVID-19 susceptibility and outcomes neither be confirmed nor excluded. Further large studies are needed to address factors associated with COVID-19 susceptibility and severity.
馃摉 Papers frequently viewed together
8 Authors (Adam L. Booth, ..., Diwakar Mohan)
#1Abdorreza Naser Moghadasi (Tehran University of Medical Sciences)H-Index: 14
#2Omid Mirmosayyeb (Tehran University of Medical Sciences)H-Index: 12
Last. Mahsa Ghajarzadeh (Tehran University of Medical Sciences)H-Index: 17
view all 5 authors...
BACKGROUND: The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS. METHODS: Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR c...
#1Jeffrey A. SparksH-Index: 31
#2Zachary S. WallaceH-Index: 30
Last. E. MateusH-Index: 6
view all 64 authors...
OBJECTIVE: To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA) METHODS: We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021) We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis f...
OBJECTIVE We systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS). METHODS We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19. RESULTS From an initial 2,679 publications and 3,138 conference abstract...
#1Seth N Levin (Columbia University)H-Index: 3
#2Shruthi Venkatesh (University of Pittsburgh)H-Index: 1
Last. Kaho B. Onomichi (Columbia University)H-Index: 3
view all 26 authors...
OBJECTIVE: To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). METHODS: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care. RESULTS: Our cohort included 1115 pa...
#3Eric Hachulla (Lille University of Science and Technology)H-Index: 107
#4Rapha猫le Seror (Universit茅 Paris-Saclay)H-Index: 52
Last. Edouard PertuisetH-Index: 6
view all 463 authors...
Summary Background Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases. Methods In this cohort study, we analysed data from the French RMD COVID-19 cohort, whi...
#1Anthony T. Reder (U of C: University of Chicago)H-Index: 61
#2Diego Centonze (University of Rome Tor Vergata)H-Index: 96
Last. Carl de Moor (Biogen Idec)H-Index: 6
view all 14 authors...
BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS). OBJECTIVE: The objective of this study was to describe the overall risk of coronavirus disease 2019 (COVID-19) infection, severe disease course, and potential population-level predictors of COVID-19 infection...
#1Amber Salter (WashU: Washington University in St. Louis)H-Index: 26
#2Robert J. Fox (Cleveland Clinic)H-Index: 55
Last. Anne H. Cross (WashU: Washington University in St. Louis)H-Index: 82
view all 11 authors...
Importance Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. Objective To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS. Design, Setting, and Participants This analysis used deidentified, cross-sectional data on patien...
Abstract Background There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America. Objective The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19. Methods RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion...
#6Saskia Lawson-Tovey (MAHSC: Manchester Academic Health Science Centre)H-Index: 5
We thank Ben Mulhearn1 for his correspondence on our article.2 The correspondence raises the important question of whether moderate-dose to high-dose glucocorticoid (GC) therapy is an independent risk factor for COVID-19-related death or whether this association is rather due to confounding by indication. First of all, we would like to re-emphasise that causal interpretation of results based on data from a cross-sectional observational study like the one we report is not possible. The only study...
#1Don Bambino Geno Tai (Mayo Clinic)H-Index: 2
#2Aditya Shah (Mayo Clinic)H-Index: 7
Last. Mark L. Wieland (Mayo Clinic)H-Index: 24
view all 5 authors...
The COVID-19 pandemic has disproportionately affected racial and ethnic minority groups, with high rates of death in African American, Native American, and LatinX communities. While the mechanisms of these disparities are being investigated, they can be conceived as arising from biomedical factors as well as social determinants of health. Minority groups are disproportionately affected by chronic medical conditions and lower access to healthcare that may portend worse COVID-19 outcomes. Furtherm...
Cited By0
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 8
#2Omid Mirmosayyeb (IUMS: Isfahan University of Medical Sciences)H-Index: 12
Last. Nasrin Asgari (University of Southern Denmark)H-Index: 26
view all 8 authors...
Abstract null null Background null We conducted this systematic review and meta-analysis to assess the risk of coronavirus disease (COVID-19), clinical features and outcome among patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). null null null Methods null We systematically searched PubMed, Scopus, Web of Science, and Embase from December 1, 2019, to July 2, 2021. The gray literature including the references of original studies, review studies, conference abstracts, and WHO COVID-19 ...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.